Alexis Yan, an analyst from Morgan Stanley, maintained the Hold rating on MicroPort Scientific. The associated price target is HK$8.60.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alexis Yan has given his Hold rating due to a combination of factors influencing MicroPort Scientific’s financial outlook. The company’s sales projections for the first half of 2025 are expected to decline by 3.5% year-over-year, with a net loss estimated at Rmb106 million. This cautious stance is further supported by a conservative outlook on the Transcatheter Aortic Valve Implantation (TAVI) segment, leading to a 2% reduction in sales estimates for 2025-2027.
Additionally, while the net loss for 2025 is anticipated to widen to Rmb122 million, there is an expectation for earnings to reach a break-even point by 2026. Adjustments to net profit estimates for 2026-2027 reflect a slight increase and decrease, respectively, from a low base. Despite these adjustments, the price target remains unchanged, suggesting a balanced risk-reward profile that warrants a Hold rating.
According to TipRanks, Yan is ranked #4398 out of 9841 analysts.
In another report released on July 15, Nomura also maintained a Hold rating on the stock with a HK$8.81 price target.